Skip to main content
spacbrain

GreenLight Biosciences Holdings, PBC

Closed (deSPAC)

Health Care · RNA-based vaccines and therapeutics development

What it is
Biosciences GreenLight Biosciences aims to address some of the world’s biggest problems by delivering on the full potential of RNA for human health and agriculture
What it’s doing now
Merging with Environmental Impact Acquisition Corp (ENVI) — closed (despac).
What you should know
The deal carries a $275M minimum-cash condition — heavy redemptions can break it.

The business, per its filings

SEC primary

Biosciences GreenLight Biosciences aims to address some of the world’s biggest problems by delivering on the full potential of RNA for human health and agriculture. Our RNA platform allows us to research, design, and manufacture for human, animal, and plant health. In human health, this includes messenger RNA vaccines and therapeutics. In agriculture, this includes RNA to protect honeybees and a range of crops. The company’s platform is protected by numerous patents. GreenLight’s human health product candidates are in the pre-clinical stage, and its product candidates for the agriculture market are in the early stages of development or regulatory review. GreenLight is a public benefit corporation that trades under the ticker GRNA on Nasdaq. For more information, visit https://www.greenlightbiosciences.com/ GreenLight Biosciences contact: David Pesci Head of Media Relations dpesci@greenlightbio.com For press, email: press@greenlightbio.com For investors, email: investors@greenlightbio.com

Source: S-4/A, accession 0001193125-22-007945

What the company says about itself

Web research — not audited

GreenLight Biosciences develops RNA-based agricultural solutions, including insecticides and treatments for crops and bees. The company has secured regulatory authorizations and launched products such as Norroa for Varroa mites and an RNA-based insecticide receiving Belgian Emergency Use Authorization in the EU.

Markets:
Agriculture | Crop Protection | Bee Health
Products:
RNA-Based Insecticide | Norroa (RNA-Based Treatment for Varroa Mites) | RNA-Based Solution to Control Grape Powdery Mildew

Source: https://greenlightbiosciences.com/ · captured Aug 26, 2026 · marketing claims are reported as claims, never merged into the filed figures above.

The deal it’s entering

GreenLight Biosciences Holdings, PBC is merging with Environmental Impact Acquisition Corp (ENVI) currently marked Closed (deSPAC).

Headline equity value—
Minimum cash to close$275M

Structure per SEC accession(s) 0001193125-21-301564. How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is GreenLight Biosciences Holdings, PBC going public?

GreenLight Biosciences Holdings, PBC has an approved merger with the SPAC Environmental Impact Acquisition Corp (ENVI). Deal status: Closed (deSPAC).

Does GreenLight Biosciences Holdings, PBC have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.

Other health care deals